首页> 外文期刊>Practical Laboratory Medicine >Comparison of two immunoassay systems for hCGβ and PAPP-A in prenatal screening for trisomy 21, 18, and 13 in the first trimester
【24h】

Comparison of two immunoassay systems for hCGβ and PAPP-A in prenatal screening for trisomy 21, 18, and 13 in the first trimester

机译:妊娠前三个月21、18和13三体的产前筛查中两种hCGβ和PAPP-A免疫测定系统的比较

获取原文
           

摘要

Objectives The biochemical serum markers free β-human chorionic gonadotropin (hCGβ) and pregnancy associated plasma protein A (PAPP-A), used in screening for trisomy 21 (T21), trisomy 18 (T18), and trisomy 13 (T13) during the first trimester, can be measured on different laboratory instruments e.g. Kryptor (Brahms) and Cobas (Roche). We compared the performance of these two analytical instruments when used for first trimester combined testing. Design and methods Serum samples from 944 singleton pregnant women attending for first trimester combined testing were routinely assayed for hCGβ and PAPP-A on Kryptor, and re-analyzed on Cobas. In addition, serum samples from 70 pregnant women carrying a fetus affected by T21, T18 or T13, were re-assayed on Cobas. Results For the screening population, the hCGβ and PAPP-A results in multiples of the median (MoM) from Kryptor and Cobas were significantly lower on Cobas when compared to Kryptor. The number of pregnant women with a risk above 1:300 for T21 was 48 for both Cobas and Kryptor, although a few patients only had a high risk with one of the methods. Overall, the screen positive rate was 5.1% for both instruments. In the trisomy groups the calculated risks for T21, T18, and T13 agreed well between Cobas and Kryptor. Conclusions The screen positive rate for T21 (5.1%) did not differ between the two analytical platforms in our screening population, although PAPP-A measurements form Cobas were significantly lower than those from Kryptor. The calculated risks for the pregnancies affected by trisomies using hCGβ MoM and PAPP-A MoM from Kryptor agreed well with those from Cobas. Highlights ? Kryptor and Cobas have the same screen positive rate of 5.1% for trisomy 21. ? The platforms perform equally when serum markers are included in risk calculation. ? MoM values from Cobas are lower than those from Kryptor in a screening population. ? An equal number of trisomy pregnancies and false negative cases were detected.
机译:目的使用生化血清标志物游离的β-人绒毛膜促性腺激素(hCGβ)和妊娠相关血浆蛋白A(PAPP-A),用于筛查21三体(T21),18三体(T18)和13三体(T13)。可以在不同的实验室仪器上测量前三个月rypto(布拉姆斯)和科巴斯(罗氏)。我们比较了这两种分析工具在妊娠早期联合测试中的性能。设计与方法定期对944名单胎孕妇进行早孕联合检测的血清样本进行常规分析,测定K蛋白中的hCGβ和PAPP-A,然后在Cobas上进行重新分析。此外,在Cobas上重新测定了70名怀有受T21,T18或T13影响的胎儿的孕妇的血清样本。结果对于筛查人群,与CG虫相比,hCGβ和PAPP-A导致K虫和Cobas的中位数(MoM)倍数在Cobas上显着降低。尽管有少数患者仅使用一种方法具有较高的风险,但对于Cobas和Kryptor而言,T21风险高于1:300的孕妇人数为48。总体而言,两种仪器的筛查阳性率均为5.1%。在三体组中,Cobas和Kryptor对T21,T18和T13的计算得出的风险相吻合。结论在我们的筛查人群中,两个分析平台之间的T21筛查阳性率(5.1%)没有差异,尽管Cobas的PAPP-A测定显着低于Kryptor。使用来自Kryptor的hCGβMoM和PAPP-A MoM计算出的受三体症影响的怀孕风险与Cobas的风险相吻合。强调 ? 21.和Cobas的21三体筛查阳性率相同,为5.1%。当风险计算中包括血清标志物时,平台的表现均相同。 ?在筛选人群中,来自Cobas的MoM值低于来自Kryptor的MoM值。 ?检出了相等数量的三体妊娠和假阴性病例。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号